Dimethylaminomicheliolide Fumarate

N/A

Report date: 2025/08/25 20:01:49
NME

Base Information

Drug NameDimethylaminomicheliolide Fumarate
Drug Alias NameACT-001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitorsSignal transducer and activator of transcription 3 inhibitorsPyruvate kinase isozymes M1/M2 activators
TargetsSignal transducer and activator of transcription 3Nuclear factor NF-kappa-B complexPyruvate kinase isozymes M1/M2
Therapy Area/IndicationsBrain metastasesSolid tumoursOptic Neuritis +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNew Zealand +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTianjin Accendatech Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTianjin Accendatech Technology Co LtdAccendatech USA IncTianjin Xinyi Shangde Biomedical Technology Co Ltd +[6] 
Inactive CompaniesN/A
Active IndicationsBrain metastasesSolid tumoursOptic Neuritis +[12] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A